A novel imidazolate-bridged copper–zinc heterodinuclear complex as a Cu, Zn–SOD active site model

Hideki Ohtsu,*a***† Yuichi Shimazaki,***a* **Akira Odani***a* **and Osamu Yamauchi****ab*

a Department of Chemistry, Graduate School of Science, Nagoya University, Chikusa-ku, Nagoya 464-8602, Japan. E-mail: b42215a@nucc.cc.nagoya-u.ac.jp

b Research Center for Materials Science, Nagoya University, Chikusa-ku, Nagoya 464-8602, Japan.

Received (in Cambridge, UK) 2nd August 1999, Accepted 25th October 1999

A novel imidazolate-bridged Cu(ii)–Zn(ii) heterodinuclear complex of an imidazole derivative containing two metalbinding groups has been synthesized, and its structure and properties have been clarified.

Copper–zinc superoxide dismutase (Cu, Zn-SOD) contains an imidazolate-bridged Cu–Zn heterodinuclear metal center in its active site.1–3 This enzyme catalyzes the dismutation of highly toxic superoxide anion produced as a byproduct to dioxygen and hydrogen peroxide in a sequence of dispersion-controlled reactions.4 Since the enzyme structure was determined by X-ray analysis,¹ the unique active site structure attracted much attention, and a number of imidazolate-bridged complexes, such as the $Cu(II)-Cu(II)$ homodinuclear complexes by Lippard et *al.,*5 have been reported as mimics of the metal site and provided valuable insights into the structure and properties of the SOD active site. In contrast to this, only a few imidazolate-bridged $Cu(II)$ –Zn(II) heterodinuclear model complexes have so far been reported.6 Because such model complexes are often constructed by self-assembly of one or two complex units by incorporating a bridging imidazolate ring, the labile nature of $Cu(II)$ and $Zn(II)$ complexes and dissociation of self-assembled structures made it difficult to study in detail their structures in solution and SOD functions. We here report the first imidazolate-bridged Cu(II)–Zn(II) heterodinuclear complex derived from a new imidazole derivative, Hbdpi {Hbdpi = $4,5$ -bis[di(2-

Hbdpi

pyridylmethyl)aminomethyl]imidazole}, which has two sets of 3N donor groups tethered to the 4 and 5 positions of the bridging imidazole ring.

Hbdpi was prepared from imidazole-4,5-dialdehyde⁷ and bis(2-pyridylmethyl)amine by reductive aminomethylation using sodium cyanoborohydride in methanol, and was characterized by ¹H and ¹³C NMR. \ddagger The heterodinuclear Cu(II)–Zn(II) complex of bdpi, [CuZn(bdpi)(MeCN)₂](ClO₄)₃.2MeCN **1**, was obtained as crystals by mixing Hbdpi and equimolar amounts of $Cu(II)$ and $Zn(II)$ in methanol and subsequent addition of triethylamine, and the composition of the dried sample of **1** was determined by elemental analysis, ICP, and ESI-mass spectral measurements. The corresponding $Cu(II)-Cu(II)$ homodinuclear complex, $[Cu_2(bdpi)(\overline{MeCN})_2](ClO_4)_3.2H_2O$ 2 was prepared in a similar manner using two equivalents of $Cu(II)$.

The molecular structure of complex **1** was determined by Xray analysis§ and is depicted in Fig. 1. As expected, the complex has an imidazolate-bridged dinuclear structure. In line with the previous observation,6*d* the copper and zinc sites are very similar to each other and indistinguishable, because the complex has a C_{2v} -like axis and both metal sites are statistically disordered. The metal ions are both in an approximately trigonal bipyramidal geometry with four nitrogen atoms of bdpi and a nitrogen atom of the solvent MeCN coordinated. The coordination site occupied by MeCN may be susceptible to ligand substitution, providing a possible binding site for substrate superoxide. The Cu(II)–Zn(II) distance of $6.197(2)$ Å in 1 is the same as that of native Cu, Zn–SOD (6.2 Å) .¹

The electronic spectrum of an acetonitrile solution of **1** (1 mM) showed two broad d–d bands at 645 and 880 nm ($\varepsilon = 60$) and 220 M^{-1} cm⁻¹, respectively). This spectrum is very close to that of $[Cu(tpa)Cl]PF_6$ [tpa = tris(2-pyridylmethyl)amine], indicating a trigonal bipyramidal structure at the copper site.8 In addition, it exhibited an imidazolate-to- $Cu(II)$ charge transfer (CT) band at 320 nm ($\varepsilon = 1500$ M⁻¹ cm⁻¹). The intensities of the d–d and CT bands for **1** were half as strong as those observed for 2 at 645, 880 and 320 nm ($\varepsilon = 110$, 420 and 3000 M⁻¹ $cm⁻¹$, respectively). The EPR spectrum of a solution of 1 (0.5) mM) in 1:1 MeCN–MeOH at 77 K ($g_{\text{N}} = 2.10$, $g_{\text{L}} = 2.24$ and $|A_{\perp}|$ = 12.0 mT) showed a line shape characteristic of mononuclear trigonal bipyramidal $Cu(II)$ complexes,⁹ but was very different from that of **2** having a single symmetrical derivative $(g = 2.13)$, which is similar to the spectrum of the imidazolate-bridged Cu(II)-glycylglycinate complex¹⁰ and other imidazolate-bridged $Cu(II)$ – $Cu(II)$ dinuclear complexes.¹¹ These results as well as the ESI-mass spectrum in MeCN demonstrate that **1** in solution retains its imidazolate-bridged

Fig. 1 X-Ray structure of complex **1** (perchlorate ions and the MeCN molecule of crystallization are omitted for clarity, and the Cu and Zn sites were so assigned that smaller R and R_w values could be obtained). Selected bonds (Å) and angles (°): Cu(1)–N(1) 2.001(7), Cu(1)–N(3) 2.104(7), Cu(1)–N(5) 2.074(7), Cu(1)–N(7) 2.105(8), Cu(1)–N((9) 2.004(9), Zn(1)– N(2) 2.005(7), Zn(1)–N(4) 2.112(7), Zn(1)–N(6) 2.076(8), Zn(1)–N(8) 2.084(7), Zn(1)–N(10) 2.023(10), N(1)–Cu–N(3) 82.5(3), N(1)–Cu(1)– N(5) 122.5(3), N(1)–Cu(1)–N(7) 118.3(3), N(3)–Cu(1)–N(9) 172.9(3), N(2)–Zn(1)–N(4) 83.0(3), N(2)–Zn(1)–N(6) 120.3(3), N(2)–Zn(1)–N(8) 120.1(3), N(4)–Zn(1)–N(10) 174.8(3).

[†] Present address: Department of Material and Life Science, Graduate School of Engineering, Osaka University, Suita, Osaka 565-0871, Japan.

 $Cu(II)$ – $Zn(II)$ heterodinuclear structure and is not a 1:1 mixture of $Cu(II)$ – $Cu(II)$ (2) and $Zn(II)$ – $Zn(II)$ complexes. Whereas the cyclic voltammogram of **2** in MeCN exhibited two reversible redox waves at $E_{1/2}$ -0.09 and +0.19 V (*vs*. NHE), 1 showed only one reversible Cu(I)/Cu(II) redox couple at $E_{1/2}$ +0.19 V (*vs*. NHE), confirming that it has one copper ion site in the molecule. In this connection, an imidazolate-bridged asymmetric dinuclear $Cu(II)$ complex showed one broad peak in the anodic and the cathodic wave,12 and several mononuclear trigonal bipyramidal $Cu(II)$ complexes of tripodal ligands containing pyridine and imidazole donors have been reported to have $E_{1/2}$ values between -0.187 and -0.290 V *vs.* NHE.¹³ The positive shift of the $E_{1/2}$ values of **1** as compared with other mononuclear $Cu(II)$ complexes may therefore be attributed to the electronic effect of the imidazolate-bound $Zn(\text{II})$, which could be an important factor for the efficient catalytic reaction of Cu, Zn–SOD. The SOD activities of **1** and **2** have been investigated by the cytochrome c assay¹⁴ using the xanthine oxidase reaction as the source of superoxide. The IC_{50} values for 1 and 2 were determined to be $0.\overline{2}4$ and $0.32 \mu M$ [*vs.* Cu(II) ion], respectively, which are higher than the value reported for native Cu, Zn–SOD $(0.04 \mu M)^{15}$ but comparable with the values of some structurally established model complexes.6*d*,12,15 In addition, the IC_{50} value for $[Cu(tpa)(MeCN)](ClO₄)₂$ was determined to be 1.4 μ M. The difference in IC₅₀ among 1, 2 and $[Cu(tpa)(MeCN)](ClO₄)₂$ may be ascribed to the imidazolatebridge and zinc ion. The effect of zinc ion was recently reported for a Cu–Zn heterodinuclear complex prepared *in situ*, which was not structurally established.16

In conclusion, the new imidazole derivative containing two metal-binding groups incorporated $Cu(II)$ and $Zn(II)$ to form a heterodinuclear SOD model complex which was stable in solution, and the SOD activity measurements exhibited the effects of the imidazolate bridge and zinc ion on the SOD activity. Studies on the details of the SOD function and mechanism are now under way.

We are grateful to Prof. Wasuke Mori, Kanagawa University, for measurements of the magnetic susceptibility, Professor Hiromu Sakurai, Kyoto Pharmaceutical University, for measurements of the SOD activity and Sachiyo Nomura, Institute for Molecular Science, for ICP measurements. This work was supported by Grants-in-Aid for Scientific Research to A. O. (No. 07CE2003(COE)) and O. Y. (Nos. 09304062 and 09045032) from the Ministry of Education, Science, Sports and Culture of Japan, to which our thanks are due.

Notes and references

‡ *Experimental:* imidazole-4,5-dialdehyde (1.0 g, 8 mmol) was dissolved in methanol (100 ml), to which bis(2-pyridylmethyl)amine (3.2 g, 16 mmol) and a small amount of acetic acid were added. Sodium cyanotrihydroborate (1.0 g, 15.5 mmol) was then added dropwise to the mixture, and after the resulting solution had been stirred for three days at room temperature, it was acidified with concentrated HCl and concentrated almost to dryness under reduced pressure. The residue was dissolved in a saturated aqueous solution of Na₂CO₃ (50 ml) and extracted with three 50 ml portions of CHCl₃. The combined extracts were dried over Na₂SO₄ and after removal of the solvent gave a brown oily product, which was purified by silica gel column chromatography with CHCl₃-MeOH as eluent to give Hbdpi (3.16 g, 80.0%); ¹H NMR (CDCl₃, 400 MHz) δ 3.65 (s, 4H), 3.75 (s, 8H), 7.12 (m, 4H), 7.47 (dt, 4H), 7.61 (td, 4H), 7.66 (s, 1H), 8.51 (dq, 4H). 13C NMR (CDCl₃; 100 MHz) δ 48.2 (CH₂), 59.2 (CH₂), 121.7 (Py), 122.0 (Im), 123.2 (Py), 133.8 (Im), 136.2 (Py), 148.4 (Py), 158.9 (Py). Complex **1** was prepared by mixing Hbdpi (0.50 g, 1.0 mmol) with a MeOH solution of $Cu(CIO₄)₂6H₂O$ (0.370 g, 1.0 mmol) and $Zn(CIO₄)₂6H₂O$ (0.372 g, 1.0 mmol) and adding NEt_3 (138.6 µl, 1.0 mmol). After filtration, the filtrate was allowed to evaporate slowly in the open air to give [CuZn(bdpi)- (MeCN)2](ClO4)3 . 2MeCN **1** as green crystals in 67.0% yield. Elemental analysis and ICP measurement were performed for the dried sample which lost the coordinated MeCN. The ratio of $Cu(II)$ to $Zn(II)$ was determined by ICP (SEIKODENKO SPS-700) with the use of the standard solutions (1000 ppm) of Cu(II) and Zn(II) obtained from Nacalai Tesque. Anal. Calc. for $[CuZn(bdpi)](ClO₄)₃·0.25MeCN·3H₂O (C_{29.5}H_{35.75}N_{8.25}Cl₃O₁₅CuZn): C,$ 36.11; H, 3.67; N, 11.78; Cu, 6.48; Zn, 6.66. Found: C, 35.88; H, 3.56; N, 11.77; Cu, 6.46; Zn, 6.65%. ESI-mass (MeCN): m/z 816 [(M - ClO₄)⁺]. $[Cu₂(bdpi)(MeCN)₂](ClO₄)₃·2H₂O$ 2 was prepared in a similar manner by

using Hbdpi and 2 equiv. of Cu(ClO₄)₂·6H₂O. Elemental analysis and ICP measurement were performed for the dried sample. Anal. Calc. for $[Cu_2(bdpi)](ClO_4)_3$ ·MeCN $(C_{31}H_{32}N_9O_{12}Cl_3Cu_2)$: C, 38.94; H, 3.37; N, 13.18; Cu, 13.29. Found: C, 38.95; H, 3.32; N, 13.35; Cu, 13.27%. Effective magnetic moment $\mu_{\text{eff}} = 3.46 \mu_{\text{B}} (300 \text{ K}).$

§ Crystal data: 1 (green): [CuZn(bdpi)(MeCN)₂](ClO₄)₃.2MeCN, $C_{37}H_{41}N_{12}O_{13}Cl_{3}CuZn$, \overline{M} = 1083.09, triclinic, space group $\overline{P1}$, a = 14.447(1), $b = 14.561(1)$, $c = 12.214(1)$ Å, $\alpha = 108.002(7)$, $\beta =$ 106.920(7), $\gamma = 89.069(7)^\circ$, $V = 2330.3(4)$ \AA^3 , $Z = 2$, $D_c = 1.508$ g cm⁻³, 5067 reflections collected, 4821 independent reflections, 3209 reflections used, 596 variables, $R = 0.076$, $R_w = 0.110$ [$I > 2.00\sigma(I)$]. The crystal was poorly diffracting. Rigaku AFC-5R four-circle automated diffractometer with graphite monochromated Cu-K α radiation, $\lambda = 1.54178$ Å, and rotating anode generator. The structures were solved by the heavy-atom method and refined anisotropically for non-hydrogen atoms by full-matrix least-squares calculations. Hydrogen atoms for the structure were located from difference Fourier maps, and their parameters were isotropically refined. All the calculations were performed by using the teXsan crystallographic software package from the Molecular Structure Corporation. CCDC 182/1462. See http://www.rsc.org./suppdata/cc/1999/2393/ for crystallographic files in .cif format.

- 1 J. S. Richardson, K. A. Thomas, B. H. Rubin and D. C. Richardson, *Proc. Natl. Acad. Sci. USA*., 1975, **72**, 1349; J. A. Tainer, E. D. Getzoff, K. M. Beem, J. S. Richardson and D. C. Richardson, *J. Mol. Biol.*, 1982, **160**, 181.
- 2 J. A. Tainer, E. D. Getzoff, J. S. Richardson and D. C. Richardson, *Nature*, 1983, **306**, 284.
- 3 I. Bertini, L. Banci and M. Piccioli, *Coord. Chem. Rev.*, 1990, **100**, 67; J. S. Valentine, *Met. Ions Biol. Syst*., 1999, **36**, 125.
- 4 I. Fridovich, *Annu. Rev. Biochem*., 1995, **64**, 97.
- 5 G. Kolks, C. R. Frihart, H. N. Rabinowitz and S. J. Lippard, *J. Am. Chem. Soc.*, 1976, **98**, 5720; C.-L. O'Young, J. C. Dewan, H. R. Lilienthal and S. J. Lippard, *J. Am. Chem. Soc*., 1978, **100**, 7291; P. K. Coughlin, J. C. Dewan, S. J. Lippard, E. Watanabe and J.-M. Lehn, *J. Am. Chem. Soc*., 1979, **101**, 265; G. Kolks, C. R. Frihart, P. K. Coughlin and S. J. Lippard, *Inorg. Chem*. 1981, **20**, 2933; P. K. Coughlin, A. E. Martin, J. C. Dewan, E. Watanabe, J. E. Bulkowski, J.-M. Lehn and S. J. Lippard, *Inorg. Chem.*, 1984, **23**, 1004; P. K. Coughlin and S. J. Lippard, *Inorg. Chem.,* 1984, **23**, 1446.
- 6 (a) M. Sato, S. Nagae, M. Uehara and J. Nakaya, *J. Chem. Soc., Chem. Commun*., 1984, 1661; (b) Q. Lu, Q. H. Luo, A. B. Dai, Z. Y. Zhou and G. Z. Hu, *J. Chem. Soc., Chem. Commun*., 1990, 1429; (c) M. Zongwan, C. Dong, T. Wenxia, Y. Kaibei and L. Li, *Polyhedron*, 1992, **11**, 191; (d) J.-L. Pierre, P. Chautemps, S. Refaif, C. Beguin, A. E. Marzouki, G. Serratrice, E. Saint-Aman and P. Rey, *J. Am. Chem. Soc*., 1995, **117**, 1965; (e) Z.-W. Mao, M.-Q. Chen, X.-S. Tan, J. Liu and W.-X. Tang, *Inorg. Chem*., 1995, **34**, 2889.
- 7 H. Schubert and W. D. Rudorf, *Z. Chem.*, 1971, **11**, 175.
- 8 K. D. Karlin, J. C. Hayes, S. Juen, J. P. Hutchinson and J. Zubieta, *Inorg. Chem*., 1982, **21** 4106.
- 9 M. Duggan, N. Ray, B. Hathaway, G. Tomlinson, P. Brint and K. Pelin, *J. Chem. Soc., Dalton Trans*., 1980, 1342.
- 10 Y. Nakao, W. Mori, T. Sakurai and A. Nakahara, *Inorg. Chim. Acta*, 1981, **55**, 103.
- 11 M. S. Haddad and D. N. Hendrickson, *Inorg. Chem*., 1978, **17**, 2622.
- 12 G. Tabbi, W. L. Driessen, J. Reedijk, R. P. Bonomo, N. Veldman and A. L. Spek, *Inorg Chem*., 1997, **36**, 1168.
- 13 K. J. Oberhausen, R. J. O'Brien, J. F. Richardson and R. M. Buchanan, *Inorg. Chim. Acta*, 1990, **173**, 145.
- 14 C. Beauchamp and I. Fridovich, *Anal. Biochem.,* 1971, **44**, 276. Superoxide anion was generated *in situ* by the xanthine–xanthine oxidase system and detected spectrophotometrically by ferricytochrome c reduction. The SOD activity was assayed in a γ -collidine buffer (50 mM, pH 7.77, 25.0 °C) containing 10 μ M ferricytochrome *c*, 50 μ M xanthine and an appropriate amount of xanthine oxidase to cause a change of absorbance ($\Delta A_{550} = 0.025$ min⁻¹). The IC₅₀ value is defined as the 50% inhibition concentration of cytochrome *c* reduction. The inhibitory effect of $Cu(II)$ ion and its complexes used in this study on xanthine oxidase was checked prior to the assay by using the absorbance at the 295 nm peak due to uric acid at pH 7.77 (N. Cotell, J. L. Bernier, J. P. Henichart, J. P. Catteau, E. Gaydou and J. C. Wallet, *Free Rad. Biol. Med*., 1992, **13**, 221; W. S. Chang, Y. J. Lee, F. J. Lu and H. C. Chiang, *Anticancer Res*., 1993, **13**, 2165). They did not show any inhibitory effect under the experimental conditions used.
- 15 U. Weser, L. M. Schubotz and E. Lengfelder, *J. Mol. Catal.*, 1981, **13**, 249.
- 16 S. Kawabata, T. Soma and K. Ichikawa, *Chem. Lett.*, 1997, 1199.

Communication 9/06226B